Manufacturing

A World-leading Psychedelic Supply Chain Solution

As a pioneering CMO to the psychedelic sector, Psygen is committed to leading and empowering the industry by creating a robust supply chain solution – now and in the future.

The Psychedelics Industry Needs a Dedicated Manufacturer

Psygen’s 17,000 sq. ft. state-of-the art, GMP-compliant facility will enable large-scale synthesis of psychedelic compounds in a production area of 6,000 sq. ft.

Psygen has applied for a Health Canada dealer’s license which allows the manufacture, sale, import, export, and analysis of LSD, 2C-B, DMT, MDMA, psilocybin, and mescaline.

Psygen Labs

Psygen API Catalogue

TRYPTAMINES ~ PHENYLETHYLAMINES ~ ERGOLINES

Psygen offers unparalleled knowledge and manufacturing capabilities from over 50 years of experience in manufacturing psychedelic medicines.

We are proud to offer the ability to create custom compounds.

Psilocybin

MDMA

DMT

LSD

Mescaline

2C-B

5-MeO-DMT

Ibogaine

Why Synthetic?

Psygen will supply the industry with safe and reliable GMP synthetic psychedelics to enable clinicians and researchers to deliver safe treatments while achieving optimal treatment outcomes.

Our focus on synthetic compounds, Psygen is able to produce quality-consistent products on a large scale, allowing us to meet increasing demand while reducing the cost of production and indirectly protecting culturally sensitive plant populations. Psygen’s API catalogue includes psychedelics for which no natural sources exist, such as LSD, 2C-B, and MDMA.

IP

Psygen has announced two provisional patents showing evidence of improved efficiency and economics in the manufacture of psilocybin and other tryptamines, as well as news of their psilocybin already being used in a human clinical trial.

Psygen’s proprietary and patent-pending manufacturing methods deliver:

Superior quality control

Faster delivery time

Synthetic psychedelic medicines

Scalable production

GMP compliant psychedelic APIs

Expanding Access

Global access to pharmaceutical grade psychedelics is limited. Psygen works for the benefit and advancement of the psychedelic industry to expand and serve new markets.

Connecting the industry

Psygen aims to contribute to the growth of the global psychedelics research ecosystem.

Psygen will create trusting relationships shaped by ingenuity and generosity – and our belief in the value of creating positive, genuine connections.

Subscribe to our newsletter for the latest news & updates.